茚達特羅在慢性阻塞性肺疾病中的臨床應用_Chinese Journal of Respiratory and Critical Care Medicine

Authors：

王賡 , 劉婷 , 王發平 , 蒲銀 ,  毛輝

四川大學華西醫院呼吸與危重癥醫學科（四川成都 610041）;

Corresponding?author：

毛輝, Email: merrymh@126.com

Keywords：

DOI：

10.7507/1671-6205.201708050

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 王賡, 劉婷, 王發平, 蒲銀, 毛輝. 茚達特羅在慢性阻塞性肺疾病中的臨床應用. Chinese Journal of Respiratory and Critical Care Medicine, 2019, 18(3): 300-304. doi: 10.7507/1671-6205.201708050 Copy

1.	Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet, 2012, 380(9859): 2095-2128.
2.	Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary. Am J Respir Crit Care Med, 2017, 195(5): 557-582.
3.	Magnussen H, Verkindre C, Jack D, et al. Indacaterol once-daily is equally effective dosed in the evening or morning in COPD. Respir Med, 2010, 104(12): 1869-1876.
4.	Calverley PMA, Lee A, Towse L, et al. Effect of tiotropium bromide on circadian variation in airflow limitation in chronic obstructive pulmonary disease. Thorax, 2003, 58(10): 855-860.
5.	Kerwin EM, Gotfried MH, Lawrence D, et al. Efficacy and tolerability of indacaterol 75 μg once daily in patients aged ≥40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies. Clin Ther, 2011, 33(12): 1974-1984.
6.	Chowdhury BA, Seymour SM, Michele TM, et al. The risks and benefits of indacaterol - The FDA's review. New Engl J Med, 2011, 365: 2247-2249.
7.	Mahler DA, Kerstjens HA, Donohue JF, et al. Indacaterol vs tiotropium in COPD patients classified as GOLD A and B. Respir Med, 2015, 109(8): 1031-1039.
8.	Decramer M, Dahl R, Kornmann O, et al. Effects of long-acting bronchodilators in COPD patients according to COPD severity and ICS use. Respir Med, 2013, 107(2): 223-232.
9.	Kinoshita M, Lee SH, Hang LW, et al. Efficacy and safety of indacaterol 150 and 300 μg in chronic obstructive pulmonary disease patients from six Asian areas including Japan: a 12-week, placebo-controlled study. Respirology, 2012, 17(2): 379-389.
10.	Donohue JF, Betts KA, Du EX, et al. Comparative efficacy of long-acting beta 2-agonists as monotherapy for chronic obstructive pulmonary disease: a network meta-analysis. Int J Chron Obstruct Pulmon Dis, 2017, 12: 367-381.
11.	Cazzola M, Calzetta L, Puxeddu E, et al. Pharmacological characterisation of the interaction between glycopyrronium bromide and indacaterol fumarate in human isolated bronchi, small airways and bronchial epithelial cells. Respir Res, 2016, 17: 70.
12.	Chetty A, Cao GJ, Severgnini M, et al. Role of matrix metalloprotease-9 in hyperoxic injury in developing lung. Am J Physiol Lung C, 2008, 295(4): L584-L592.
13.	Klein G, Vellenga E, Fraaije MW, et al. The possible role of matrix metalloproteinase (MMP)-2 and MMP-9 in cancer, e.g. acute leukemia. Crit Rev Oncol Hemat, 2004, 50(2): 87-100.
14.	Loganathan RS, Stover DE, Shi W, et al. Prevalence of COPD in women compared to men around the time of diagnosis of primary lung cancer. Chest, 2006, 129(5): 1305-1312.
15.	Cazzola M, Page CP, Calzetta L, et al. Pharmacology and therapeutics of bronchodilators. Pharmacol Rev, 2012, 64(3): 450-504.
16.	Cazzola M, Molimard M. The scientific rationale for combining long-acting β₂-agonists and muscarinic antagonists in COPD. Pulm Pharmacol Ther, 2010, 23(4): 257-267.
17.	Mahler DA, D'Urzo A, Bateman ED, et al. Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparison. Thorax, 2012, 67(9): 781-788.
18.	Tashkin DP, Ferguson GT. Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease. Respir Res, 2013, 14: 49.
19.	van Noord JA, Buhl R, Laforce C, et al. QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease. Thorax, 2010, 65(12): 1086-1091.
20.	Blair HA, Deeks ED. Umeclidinium/vilanterol: a review of its use as maintenance therapy in adults with chronic obstructive pulmonary disease. Drugs, 2015, 75(1): 61-74.
21.	Buhl R, Banerji D. Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD. Int J Chron Obstruct Pulmon Dis, 2012, 7: 729-741.
22.	Dahl R, Chapman KR, Rudolf M, et al. Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: The ENLIGHTEN study. Respir Med, 2013, 107(10): 1558-1567.
23.	Bateman ED, Ferguson GT, Barnes N, et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur Respir J, 2013, 42(6): 1484-1494.
24.	Wedzicha JA, Decramer M, Ficker JH, et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir Med, 2013, 1(3): 199-209.
25.	Wedzicha JA, Zhong NS, Ichinose M, et al. Indacaterol/glycopyrronium versus salmeterol/fluticasone in Asian patients with COPD at a high risk of exacerbations: results from the FLAME study. Int J Chron Obstruct Pulmon Dis, 2017, 12: 339-349.
26.	Wedzicha JA, Banerji D, Chapman KR, et al. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. N Engl J Med, 2016, 374(23): 2222-2234.
27.	Zhong N, Wang C, Zhou X, et al. LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD. Int J Chron Obstruct Pulmon Dis, 2015, 10: 1015-1026.
28.	Vogelmeier CF, Gaga M, Aalamian-Mattheis M, et al. Efficacy and safety of direct switch to indacaterol/glycopyrronium in patients with moderate COPD: the CRYSTAL open-label randomised trial. Respir Res, 2017, 18: 140.
29.	Buhl R, Gessner C, Schuermann W, et al. Efficacy and safety of once-daily QVA149 compared with the free combination of once-daily tiotropium plus twice-daily formoterol in patients with moderate-to-severe COPD (QUANTIFY): a randomised, non-inferiority study. Thorax, 2015, 70(4): 311-319.
30.	Joshi T, Johnson M, Newton R, et al. The long-acting beta2 -adrenoceptor agonist, indacaterol, enhances glucocorticoid receptor-mediated transcription in human airway epithelial cells in a gene- and agonist-dependent manner. Br J Pharmacol, 2015, 172(10): 2634-2653.
31.	Beeh KM, Kirsten AM, Tanase AM, et al. Indacaterol acetate/mometasone furoate provides sustained improvements in lung function compared with salmeterol xinafoate/fluticasone propionate in patients with moderate-to-very-severe COPD: results from a phase II randomized, double-blind 12-week study. Int J Chron Obstruct Pulmon Dis, 2018, 13: 3923-3936.
32.	Frith PA, Thompson PJ, Ratnavadivel R, et al. Glycopyrronium once-daily significantly improves lung function and health status when combined with salmeterol/fluticasone in patients with COPD: the GLISTEN study - a randomised controlled trial. Thorax, 2015, 70(6): 519-527.
33.	Singh D, Brooks J, Hagan G, et al. Superiority of "triple'' therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD. Thorax, 2008, 63(7): 592-598.
34.	Singh D, Papi A, Corradi M, et al. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β₂-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial. Lancet, 2016, 388(10048): 963-973.
35.	Juvelekian G, El-Sorougi W, Pothirat C, et al. A real-world evaluation of indacaterol and other bronchodilators in COPD: the INFLOW study. Int J Chron Obstruct Pulmon Dis, 2015, 10: 2109-2120.
36.	Chapman KR, Fogarty CM, Peckitt C, et al. Delivery characteristics and patients' handling of two single-dose dry-powder inhalers used in COPD. Int J Chron Obstruct Pulmon Dis, 2011, 6: 353-363.
37.	Bosnic-Anticevich S, Chrystyn H, Costello RW, et al. The use of multiple respiratory inhalers requiring different inhalation techniques has an adverse effect on COPD outcomes. Int J Chron Obstruct Pulmon Dis, 2017, 12: 59-71.
38.	Ulrik CS. Clinical benefit of fixed-dose dual bronchodilation with glycopyrronium and indacaterol once daily in patients with chronic obstructive pulmonary disease: a systematic review. Int J Chron Obstruct Pulmon Dis, 2014, 9: 331-338.
39.	Ribeiro M, Chapman KR. Comparative efficacy of indacaterol in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis, 2012, 7: 145-152.
40.	Donohue JF, Singh D, Kornmann O, et al. Safety of indacaterol in the treatment of patients with COPD. Int J Chron Obstruct Pulmon Dis, 2011, 6: 477-492.
41.	Price D, Ostrem A, Thomas M, Welte T. Dual bronchodilation in COPD: lung function and patient-reported outcomes - a review. Int J Chron Obstruct Pulmon Dis, 2017, 12: 141-168.
42.	Shimada S, Vaidya S, Khindri S, et al. Pharmacokinetics of QMF149 in Japanese versus Caucasian subjects: an open-label, randomized phase I study. Int J Clin Pharmacol Ther, 2015, 53(5): 398-407.

1. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet, 2012, 380(9859): 2095-2128.
2. Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary. Am J Respir Crit Care Med, 2017, 195(5): 557-582.
3. Magnussen H, Verkindre C, Jack D, et al. Indacaterol once-daily is equally effective dosed in the evening or morning in COPD. Respir Med, 2010, 104(12): 1869-1876.
4. Calverley PMA, Lee A, Towse L, et al. Effect of tiotropium bromide on circadian variation in airflow limitation in chronic obstructive pulmonary disease. Thorax, 2003, 58(10): 855-860.
5. Kerwin EM, Gotfried MH, Lawrence D, et al. Efficacy and tolerability of indacaterol 75 μg once daily in patients aged ≥40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies. Clin Ther, 2011, 33(12): 1974-1984.
6. Chowdhury BA, Seymour SM, Michele TM, et al. The risks and benefits of indacaterol - The FDA's review. New Engl J Med, 2011, 365: 2247-2249.
7. Mahler DA, Kerstjens HA, Donohue JF, et al. Indacaterol vs tiotropium in COPD patients classified as GOLD A and B. Respir Med, 2015, 109(8): 1031-1039.
8. Decramer M, Dahl R, Kornmann O, et al. Effects of long-acting bronchodilators in COPD patients according to COPD severity and ICS use. Respir Med, 2013, 107(2): 223-232.
9. Kinoshita M, Lee SH, Hang LW, et al. Efficacy and safety of indacaterol 150 and 300 μg in chronic obstructive pulmonary disease patients from six Asian areas including Japan: a 12-week, placebo-controlled study. Respirology, 2012, 17(2): 379-389.
10. Donohue JF, Betts KA, Du EX, et al. Comparative efficacy of long-acting beta 2-agonists as monotherapy for chronic obstructive pulmonary disease: a network meta-analysis. Int J Chron Obstruct Pulmon Dis, 2017, 12: 367-381.
11. Cazzola M, Calzetta L, Puxeddu E, et al. Pharmacological characterisation of the interaction between glycopyrronium bromide and indacaterol fumarate in human isolated bronchi, small airways and bronchial epithelial cells. Respir Res, 2016, 17: 70.
12. Chetty A, Cao GJ, Severgnini M, et al. Role of matrix metalloprotease-9 in hyperoxic injury in developing lung. Am J Physiol Lung C, 2008, 295(4): L584-L592.
13. Klein G, Vellenga E, Fraaije MW, et al. The possible role of matrix metalloproteinase (MMP)-2 and MMP-9 in cancer, e.g. acute leukemia. Crit Rev Oncol Hemat, 2004, 50(2): 87-100.
14. Loganathan RS, Stover DE, Shi W, et al. Prevalence of COPD in women compared to men around the time of diagnosis of primary lung cancer. Chest, 2006, 129(5): 1305-1312.
15. Cazzola M, Page CP, Calzetta L, et al. Pharmacology and therapeutics of bronchodilators. Pharmacol Rev, 2012, 64(3): 450-504.
16. Cazzola M, Molimard M. The scientific rationale for combining long-acting β₂-agonists and muscarinic antagonists in COPD. Pulm Pharmacol Ther, 2010, 23(4): 257-267.
17. Mahler DA, D'Urzo A, Bateman ED, et al. Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparison. Thorax, 2012, 67(9): 781-788.
18. Tashkin DP, Ferguson GT. Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease. Respir Res, 2013, 14: 49.
19. van Noord JA, Buhl R, Laforce C, et al. QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease. Thorax, 2010, 65(12): 1086-1091.
20. Blair HA, Deeks ED. Umeclidinium/vilanterol: a review of its use as maintenance therapy in adults with chronic obstructive pulmonary disease. Drugs, 2015, 75(1): 61-74.
21. Buhl R, Banerji D. Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD. Int J Chron Obstruct Pulmon Dis, 2012, 7: 729-741.
22. Dahl R, Chapman KR, Rudolf M, et al. Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: The ENLIGHTEN study. Respir Med, 2013, 107(10): 1558-1567.
23. Bateman ED, Ferguson GT, Barnes N, et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur Respir J, 2013, 42(6): 1484-1494.
24. Wedzicha JA, Decramer M, Ficker JH, et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir Med, 2013, 1(3): 199-209.
25. Wedzicha JA, Zhong NS, Ichinose M, et al. Indacaterol/glycopyrronium versus salmeterol/fluticasone in Asian patients with COPD at a high risk of exacerbations: results from the FLAME study. Int J Chron Obstruct Pulmon Dis, 2017, 12: 339-349.
26. Wedzicha JA, Banerji D, Chapman KR, et al. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. N Engl J Med, 2016, 374(23): 2222-2234.
27. Zhong N, Wang C, Zhou X, et al. LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD. Int J Chron Obstruct Pulmon Dis, 2015, 10: 1015-1026.
28. Vogelmeier CF, Gaga M, Aalamian-Mattheis M, et al. Efficacy and safety of direct switch to indacaterol/glycopyrronium in patients with moderate COPD: the CRYSTAL open-label randomised trial. Respir Res, 2017, 18: 140.
29. Buhl R, Gessner C, Schuermann W, et al. Efficacy and safety of once-daily QVA149 compared with the free combination of once-daily tiotropium plus twice-daily formoterol in patients with moderate-to-severe COPD (QUANTIFY): a randomised, non-inferiority study. Thorax, 2015, 70(4): 311-319.
30. Joshi T, Johnson M, Newton R, et al. The long-acting beta2 -adrenoceptor agonist, indacaterol, enhances glucocorticoid receptor-mediated transcription in human airway epithelial cells in a gene- and agonist-dependent manner. Br J Pharmacol, 2015, 172(10): 2634-2653.
31. Beeh KM, Kirsten AM, Tanase AM, et al. Indacaterol acetate/mometasone furoate provides sustained improvements in lung function compared with salmeterol xinafoate/fluticasone propionate in patients with moderate-to-very-severe COPD: results from a phase II randomized, double-blind 12-week study. Int J Chron Obstruct Pulmon Dis, 2018, 13: 3923-3936.
32. Frith PA, Thompson PJ, Ratnavadivel R, et al. Glycopyrronium once-daily significantly improves lung function and health status when combined with salmeterol/fluticasone in patients with COPD: the GLISTEN study - a randomised controlled trial. Thorax, 2015, 70(6): 519-527.
33. Singh D, Brooks J, Hagan G, et al. Superiority of "triple'' therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD. Thorax, 2008, 63(7): 592-598.
34. Singh D, Papi A, Corradi M, et al. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β₂-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial. Lancet, 2016, 388(10048): 963-973.
35. Juvelekian G, El-Sorougi W, Pothirat C, et al. A real-world evaluation of indacaterol and other bronchodilators in COPD: the INFLOW study. Int J Chron Obstruct Pulmon Dis, 2015, 10: 2109-2120.
36. Chapman KR, Fogarty CM, Peckitt C, et al. Delivery characteristics and patients' handling of two single-dose dry-powder inhalers used in COPD. Int J Chron Obstruct Pulmon Dis, 2011, 6: 353-363.
37. Bosnic-Anticevich S, Chrystyn H, Costello RW, et al. The use of multiple respiratory inhalers requiring different inhalation techniques has an adverse effect on COPD outcomes. Int J Chron Obstruct Pulmon Dis, 2017, 12: 59-71.
38. Ulrik CS. Clinical benefit of fixed-dose dual bronchodilation with glycopyrronium and indacaterol once daily in patients with chronic obstructive pulmonary disease: a systematic review. Int J Chron Obstruct Pulmon Dis, 2014, 9: 331-338.
39. Ribeiro M, Chapman KR. Comparative efficacy of indacaterol in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis, 2012, 7: 145-152.
40. Donohue JF, Singh D, Kornmann O, et al. Safety of indacaterol in the treatment of patients with COPD. Int J Chron Obstruct Pulmon Dis, 2011, 6: 477-492.
41. Price D, Ostrem A, Thomas M, Welte T. Dual bronchodilation in COPD: lung function and patient-reported outcomes - a review. Int J Chron Obstruct Pulmon Dis, 2017, 12: 141-168.
42. Shimada S, Vaidya S, Khindri S, et al. Pharmacokinetics of QMF149 in Japanese versus Caucasian subjects: an open-label, randomized phase I study. Int J Clin Pharmacol Ther, 2015, 53(5): 398-407.

Previous Article
慢性阻塞性肺疾病合并胃食管反流病的研究進展
Next Article
氫氣在呼吸系統疾病模型中的應用及相關機制研究進展

Chinese Journal of Respiratory and Critical Care Medicine

茚達特羅在慢性阻塞性肺疾病中的臨床應用

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content